Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production.

ABSTRACT:

Introduction

Reducing brain levels of both soluble and insoluble forms of amyloid beta (Aβ) remains the primary goal of most therapies that target Alzheimer's disease (AD). However, no treatment has so far resulted in patient benefit, and clinical trials of the most promising drug candidates have generally failed due to significant adverse effects. This highlights the need for safer and more selective ways to target and modulate Aβ biogenesis.

Methods

Peptide technology has advanced to allow reliable synthesis, purification, and delivery of once-challenging hydrophobic sequences. This is opening up new routes to target membrane processes associated with disease. Here we deploy a combination of atomic detail molecular dynamics (MD) simulations, living-cell Förster resonance e

SUBMITTER: Khan A 

PROVIDER: S-EPMC10632552 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature